Sinclair Pharma (SPH): Demand growing in target markets
In 2016 Sinclair was transformed into a streamlined, pure-play aesthetics company with a concentrated, competitive portfolio of differentiated injectable products. Effective, longer-lasting, natural looking, minimally invasive treatments are benefiting from trends away from intensive plastic surgery and represent a major growth opportunity. Strong Silhouette sales in the US and Brazil, and declining Sculptra sales are pushing gross margins >70%. Demand in Brazil, the US, and China is set to deliver major value following approvals in the near- and mid-term. In market US demand has lifted InstaLift sales to $2.9m/£2.3m.
We are a rapidly growing, innovative corporate research & consultancy business, based in London, serving the needs of both public and private companies.
Our expert team of sector analysts and market professionals collectively have over 400 years of experience. This depth of knowledge and a reputation for integrity have built trust with investors. With effective communication and precision distribution, we help companies disseminate their investment message to interested investors, as well as advise them on strategy.
Our smaller, boutique structure allows us to provide first-class customer service and to deliver a wide range of ad-hoc services for multiple clients with different needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.